Tag: pharmaceuticals
-
Sanofi, Alphabet Create Diabetes Venture
Drug maker Sanofi and Verily Life Sciences, a division of Alphabet — parent company of Google — are creating Onduo, a joint venture to develop health management solutions for people with diabetes.
-
Trial Testing Diabetes Drug as Parkinson’s Treatment
A clinical trial has started to test a current drug for type 2 diabetes as a treatment for Parkinson’s disease.
-
Nanoparticle Therapy Start-Up Gains $4M in Early Funds
A start-up enterprise developing treatments for autoimmune disorders using protein-laden nanoparticles is raising $4 million in its first venture funding round.
-
Small Business Grant Funds Flu Therapy R&D
A biotechnology company in South Dakota is developing an influenza therapy, with backing from a National Institutes of Health program supporting research by small enterprises.
-
Orphan Status Granted for Hemophilia Genome Editing
Treatments using genome-editing techniques for hemophilia B, a rare blood clotting disease, received orphan therapy status from the U.S. Food and Drug Administration.
-
Chip Device Speeds Single Cell Analysis
A microfluidic, or lab-on-a-chip, device speeds the analysis of individual cells, which its developers show can be applied immediately to testing antibiotics.
-
Takeda Awarded $19.8 Million for Zika Vaccine
Takeda Pharmaceutical Company is receiving $19.8 million from a U.S. public health agency for initial steps to develop a vaccine to prevent Zika infections.
-
Trial Shows Antibody Slows Alzheimer’s Cognitive Decline
A clinical trial shows older individuals with early or mild cases of Alzheimer’s disease treated for a year with an engineered human antibody have less decline in mental functions associated with Alzheimer’s disease.
-
Sleeping Sickness Treatment Found in Cancer Drug
An experimental drug designed to treat solid tumor cancers was shown in lab tests to rid mice of human African trypanosomiasis, also known as sleeping sickness.
-
Small Molecule Drug Discovery Patent Issued
A company developing small-molecule treatments for biological targets considered difficult to address is receiving a patent for its core drug identification technology.